Geo Group Inc (The) REIT vs Illumina, Inc. — how do they compare? Geo Group Inc (The) REIT trades at $30.96 (market cap $4.02B), while Illumina, Inc. trades at $265 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 10.1× Geo Group Inc (The) REIT's market cap, and Illumina, Inc. is more actively traded (2,948,626 versus 2,693,825). Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 0 Days and Illumina, Inc. for 83 Days on average.
| GEO | ILMN | |
|---|---|---|
Market Cap | $4.02B | $40.43B |
Volume | 2,693,825 | 2,948,626 |
Sector | Industrials | Health |
52-Week High | $32.77 | $293.69 |
52-Week Low | $13.26 | $91.00 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $5.57B | $41.79B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →